U.S. Markets close in 6 hrs 3 mins
  • S&P 500

    3,824.74
    +25.83 (+0.68%)
     
  • Dow 30

    31,025.61
    +95.09 (+0.31%)
     
  • Nasdaq

    13,362.78
    +165.60 (+1.25%)
     
  • Russell 2000

    2,165.98
    +14.84 (+0.69%)
     
  • Crude Oil

    53.67
    +0.69 (+1.30%)
     
  • Gold

    1,861.00
    +20.80 (+1.13%)
     
  • Silver

    25.67
    +0.35 (+1.40%)
     
  • EUR/USD

    1.2086
    -0.0047 (-0.3868%)
     
  • 10-Yr Bond

    1.1010
    +0.0090 (+0.82%)
     
  • Vix

    22.47
    -0.77 (-3.31%)
     
  • GBP/USD

    1.3643
    +0.0009 (+0.0628%)
     
  • USD/JPY

    103.7500
    -0.1420 (-0.1367%)
     
  • BTC-USD

    34,986.12
    +381.57 (+1.10%)
     
  • CMC Crypto 200

    689.98
    -10.63 (-1.52%)
     
  • FTSE 100

    6,721.38
    +8.43 (+0.13%)
     
  • Nikkei 225

    28,523.26
    -110.24 (-0.39%)
     

Penumbra Class Action Reminder

Newsfile Corp.
·2 min read

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Penumbra To Contact Him Directly To Discuss Their Options

New York, New York--(Newsfile Corp. - December 20, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Penumbra, Inc. ("Penumbra" or the "Company") (NYSE:PEN).

If you suffered losses exceeding $50,000 investing in Penumbra stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/PEN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

There is no cost or obligation to you.

On November 10, 2020, Quintessential Capital Management issued a research report on Penumbra entitled "Penumbra and its 'Killer Catheter': A tale of corporate greed and seemingly blatant disregard for patients' lives[.]"

Then, on December 8, 2020, Quintessential Capital Management released a follow-up research report entitled "Is Penumbra's core scientific research authored by a fake person?: The incredible story of Penumbra's Dr. Antik Bose[.]" The report alleged that some of the Company's scientific research appear to have been incorrectly credited or even authored by a fake individual.

On the news of the report, Penumbra's stock price fell $19.95 per share, or 8.91%, to close at $204.07 per share on December 8, 2020.

Then, on December 15, 2020, after the market, Penumbra announced that it was voluntarily "recalling its JET 7 Xtra Flex because the catheter may become susceptible to distal tip damage during use[, which] may result in potential vessel damage, and subsequent patient injury or death."

On this news, Penumbra's stock price fell $13.84 per share, or 7.33%, to a close of $174.98 per share on December 16, 2020.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70677